CTKB vs GS · rev $200.5M vs P/E 20, $324.25B cap
Cytek Biosciences Inc (CTKB) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
Cytek Biosciences Inc (CTKB) is a medical devices company listed on US.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Latest reported CTKB revenue for 2024-12-31 was $200.5M. Net income was -$6.0M. Revenue was up 3.9% from 2023-12-31 to 2024-12-31. CTKB currently screens at market cap $421.8M.
GS does not have a complete income-statement cache yet.
CTKB currently screens at market cap $421.8M. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the CTKB and GS stock pages for the full models.
Not investment advice.